Evidence map›Paper›PMID 37986195›Full record

ArticleArchives of public health = Archives belges de sante publique2023

Community evaluation of the physical and insecticidal durability of DuraNet® Plus, an alpha-cypermethrin and piperonyl butoxide incorporated mosquito net: protocol for a multi-country study in West, Central and East Africa.

Abel Agbevo, Idelphonse Ahogni, Benjamin Menze, Patrick Tungu, Elison E Kemibala, Renaud Govoetchan, Charles Wondji, Germain Gil Padonou, Corine Ngufor

Open access · goldAbstract read
In one paragraph

Article in Archives of public health = Archives belges de sante publique, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Abel AgbevoCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Idelphonse AhogniCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Benjamin MenzeCentre for Research in Infectious Diseases (CRID) ), Yaoundé, Cameroon.
Patrick TunguVector Control Training Centre (VCTC), Muheza, Tanzania.
Elison E KemibalaVector Control Training Centre (VCTC), Muheza, Tanzania.
Renaud GovoetchanCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Charles WondjiCentre for Research in Infectious Diseases (CRID) ), Yaoundé, Cameroon.
Germain Gil PadonouCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin.
Corine NguforCentre de Recherches Entomologiques de Cotonou (CREC), Cotonou, Benin. corine.ngufor@lshtm.ac.uk.
London School of Hygiene & Tropical Medicine · GBMinistry of Scientific Research and Innovation · CMNational Institute for Medical Research · TZVector & Vector-Borne Diseases Research Institute · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPyrethroid-PBO nets have demonstrated improved impact against clinical malaria transmitted by pyrethroid resistant mosquito vectors and are being scaled up across Africa. However very little is known about their physical and insecticidal durability under operational conditions. This study will investigate the attrition, fabric integrity, insecticide content and bioefficacy of DuraNet® Plus, a new WHO prequalified alphacypermethrin and PBO incorporated net developed by Shobikaa Impex Private Limited over 3 years of field use in communities in Benin, Cameroon and Tanzania.

methodsThe study will be conducted in parallel in selected villages in Zakpota District in Benin, Mbalmayo, District in Cameroon and Muheza District in Tanzania. In each country, ~ 1800 households will be recruited and randomised to receive DuraNet® Plus or DuraNet® (a WHO prequalified alphacypermethrin-only ITN). Follow up surveys will be performed at 1 month post distribution to investigate adverse events and subsequently every 6-12 months to assess ITN attrition and fabric integrity following standard WHO procedures. A second cohort of nets will be withdrawn every 6-12 months and assessed for alpha-cypermethrin and PBO content and for entomological activity in laboratory bioassays (cone bioassays and tunnel tests). Alpha-cypermethrin bioefficacy will be monitored using the susceptible Anopheles gambiae Kisumu strain in cone bioassays while PBO bioefficacy will be monitored using pyrethroid resistant strains with overexpressed P450 enzymes in tunnel tests to determine the proportion of efficacious nets (≥ 95% knockdown, ≥ 80% mortality or ≥ 90% blood feeding inhibition in tunnels) at each time point. Nets withdrawn at 12, 24 and 36 months from each country will also be tested in experimental hut trials against wild free-flying pyrethroid resistant Anopheles gambiae sl in Côvè Benin to investigate the superiority of DuraNet® Plus over DuraNet® at each time point under semi field conditions.

conclusionThis large-scale multi country trial will provide useful information on the durability of a pyrethroid-PBO net (DuraNet® Plus) in 3 different regions in sub-Saharan Africa. The methods proposed for bioefficacy testing could also contribute towards the development of new standardised guidelines for monitoring the insecticidal efficacy of pyrethroid-PBO nets under operational conditions.

Indexed as

BioefficacyDurabilityDuraNet®DuraNet® PlusInsecticideInsecticide treated netITNLLINMalariaPBOPiperonyl Butoxide

Identifiers

PMID37986195
PMCPMC10662531
OpenAlexW4388844042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.